Cited by 91

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Human Papillomavirus 16 E7 Oncoprotein Attenuates DNA Damage Checkpoint Control by Increasing the Proteolytic Turnover of Claspin

Spardy, Nicole, Covella, Kathryn, Cha, Elliot, Hoskins, Elizabeth E., Wells, Susanne I., Duensing, Anette, Duensing, Stefan·2009·Cancer Research

Published version of a preprint

Abstract

The human papillomavirus (HPV) 16 E7 oncoprotein has been reported previously to stimulate DNA damage and to activate host cell DNA damage checkpoints. How HPV-16 E7 maintains proliferation despite activated DNA damage checkpoints is incompletely understood. Here, we provide evidence that cells expressing the HPV-16 E7 oncoprotein can enter mitosis in the presence of DNA damage. We show that this activity of HPV-16 E7 involves attenuation of DNA damage checkpoint control by accelerating the proteolytic turnover of claspin. Claspin mediates the activation of CHK1 by ATR in response to replication stress, and its degradation plays a critical role in DNA damage checkpoint recovery. Expression of a nondegradable mutant of claspin was shown to inhibit mitotic entry in HPV-16 E7–expressing cells. Multiple components of the SCFβ-TrCP–based claspin degradation machinery were found deregulated in the presence of HPV-16 E7, including cullin 1, β-TrCP, Aurora A, and Polo-like kinase-1 (PLK1). In contrast, no difference in the expression level of the claspin deubiquitinating enzyme USP7 was detected. Levels of Aurora A and PLK1 as well as phosphorylated PLK1 at threonine 210, a prerequisite for DNA damage checkpoint recovery, remained detectable following replication stress in HPV-16 E7–expressing cells but not in control cells. In summary, our results suggest that the HPV-16 E7 oncoprotein alleviates DNA damage checkpoint responses and promotes mitotic entry by accelerating claspin degradation through a mechanism that involves deregulation of components of the SCFβ-TrCP–based claspin degradation machinery. [Cancer Res 2009;69(17):7022–9]

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-09-0925

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 38

  1. zur Hausen H. Papillomaviruses in the causation of human cancers—a brief historical account. Virology 2009; 384: 260–5. · DOI · Paper page
  2. Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res 2002; 89: 213–28. · DOI
  3. Munger K, Basile JR, Duensing S, et al. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 2001; 20: 7888–98. · DOI
  4. Jones DL, Alani RM, Munger K. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. Genes Dev 1997; 11: 2101–11. · DOI · Paper page
  5. Funk JO, Waga S, Harry JB, Espling E, Stillman B, Galloway DA. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev 1997; 11: 2090–100. · DOI · Paper page
  6. Zerfass-Thome K, Zwerschke W, Mannhardt B, Tindle R, Botz JW, Jansen-Durr P. Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene 1996; 13: 2323–30.
  7. Longworth MS, Laimins LA. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 2004; 68: 362–72. · DOI
  8. Klingelhutz AJ, Foster SA, McDougall JK. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 1996; 380: 79–82. · DOI · Paper page
  9. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129–36. · DOI · Paper page
  10. DiMaio D, Liao JB. Human papillomaviruses and cervical cancer. Adv Virus Res 2006; 66: 125–59. · DOI
  11. Tanaka S, Diffley JF. Deregulated G1-cyclin expression induces genomic instability by preventing efficient pre-RC formation. Genes Dev 2002; 16: 2639–49. · DOI
  12. Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434: 864–70. · DOI · Paper page
  13. Ekholm-Reed S, Mendez J, Tedesco D, Zetterberg A, Stillman B, Reed SI. Deregulation of cyclin E in human cells interferes with prereplication complex assembly. J Cell Biol 2004; 165: 789–800. · DOI
  14. Spardy N, Duensing A, Charles D, et al. The human papillomavirus type 16 E7 oncoprotein activates the Fanconi anemia (FA) pathway and causes accelerated chromosomal instability in FA cells. J Virol 2007; 81: 13265–70. · DOI
  15. Howlett NG, Taniguchi T, Durkin SG, D'Andrea AD, Glover TW. The Fanconi anemia pathway is required for the DNA replication stress response and for the regulation of common fragile site stability. Hum Mol Genet 2005; 14: 693–701. · DOI
  16. Liu X, Han S, Baluda MA, Park NH. HPV-16 oncogenes E6 and E7 are mutagenic in normal human oral keratinocytes. Oncogene 1997; 14: 2347–53. · DOI
  17. Duensing S, Munger K. The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res 2002; 62: 7075–82.
  18. Kessis TD, Connolly DC, Hedrick L, Cho KR. Expression of HPV16 E6 or E7 increases integration of foreign DNA. Oncogene 1996; 13: 427–31.
  19. Song S, Gulliver GA, Lambert PF. Human papillomavirus type 16 E6 and E7 oncogenes abrogate radiation-induced DNA damage responses in vivo through p53-dependent and p53-independent pathways. Proc Natl Acad Sci U S A 1998; 95: 2290–5. · DOI
  20. Helt AM, Galloway DA. Destabilization of the retinoblastoma tumor suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human keratinocytes. J Virol 2001; 75: 6737–47. · DOI · Paper page
  21. O'Connell MJ, Walworth NC, Carr AM. The G2-phase DNA-damage checkpoint. Trends Cell Biol 2000; 10: 296–303. · DOI
  22. Kumagai A, Dunphy WG. Claspin, a novel protein required for the activation of Chk1 during a DNA replication checkpoint response in Xenopus egg extracts. Mol Cell 2000; 6: 839–49. · DOI · Paper page
  23. Chini CC, Chen J. Claspin, a regulator of Chk1 in DNA replication stress pathway. DNA Repair (Amst) 2004; 3: 1033–7. · DOI
  24. Mailand N, Bekker-Jensen S, Bartek J, Lukas J. Destruction of claspin by SCFβTrCP restrains Chk1 activation and facilitates recovery from genotoxic stress. Mol Cell 2006; 23: 307–18. · DOI · Paper page
  25. Macurek L, Lindqvist A, Lim D, et al. Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature 2008; 455: 119–23. · DOI
  26. Bassermann F, Frescas D, Guardavaccaro D, Busino L, Peschiaroli A, Pagano M. The Cdc14B-Cdh1-1 axis controls the G2 DNA-damage-response checkpoint. Cell 2008; 134: 256–67. · DOI · Paper page
  27. Zhang D, Zaugg K, Mak TW, Elledge SJ. A role for the deubiquitinating enzyme USP28 in control of the DNA-damage response. Cell 2006; 126: 529–42. · DOI
  28. Lupardus PJ, Cimprich KA. Checkpoint adaptation; molecular mechanisms uncovered. Cell 2004; 117: 555–6. · DOI
  29. Yoo HY, Kumagai A, Shevchenko A, Dunphy WG. Adaptation of a DNA replication checkpoint response depends upon inactivation of claspin by the Polo-like kinase. Cell 2004; 117: 575–88. · DOI · Paper page
  30. Toczyski DP, Galgoczy DJ, Hartwell LH. CDC5 and CKII control adaptation to the yeast DNA damage checkpoint. Cell 1997; 90: 1097–106. · DOI
  31. Sandell LL, Zakian VA. Loss of a yeast telomere: arrest, recovery, and chromosome loss. Cell 1993; 75: 729–39. · DOI
  32. Syljuasen RG, Jensen S, Bartek J, Lukas J. Adaptation to the ionizing radiation-induced G2 checkpoint occurs in human cells and depends on checkpoint kinase 1 and Polo-like kinase 1 kinases. Cancer Res 2006; 66: 10253–7. · DOI
  33. Lindon C, Pines J. Ordered proteolysis in anaphase inactivates Plk1 to contribute to proper mitotic exit in human cells. J Cell Biol 2004; 164: 233–41. · DOI
  34. Uchiumi T, Longo DL, Ferris DK. Cell cycle regulation of the human polo-like kinase (PLK) promoter. J Biol Chem 1997; 272: 9166–74. · DOI
  35. Kimura M, Kotani S, Hattori T, et al. Cell cycle-dependent expression and spindle pole localization of a novel human protein kinase, Aik, related to Aurora of Drosophila and yeast Ipl1. J Biol Chem 1997; 272: 13766–71. · DOI
  36. Iwanaga R, Komori H, Ishida S, et al. Identification of novel E2F1 target genes regulated in cell cycle-dependent and independent manners. Oncogene 2006; 25: 1786–98. · DOI
  37. He L, Yang H, Ma Y, Pledger WJ, Cress WD, Cheng JQ. Identification of Aurora-A as a direct target of E2F3 during G2-M cell cycle progression. J Biol Chem 2008; 283: 31012–20. · DOI
  38. Ishida S, Huang E, Zuzan H, et al. Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis. Mol Cell Biol 2001; 21: 4684–99. · DOI

Metadata

Authors
Spardy, N., Covella, K., Cha, E., Hoskins, E. E., Wells, S. I., Duensing, A., & Duensing, S.
Affiliations
  • 1Biochemistry and Molecular Genetics Graduate Program, Departments of
  • 4Molecular Virology Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania; and
  • 5Division of Hematology and Oncology, Cincinnati's Children's Hospital Medical Center, Cincinnati, Ohio
  • 2Pathology and
  • 3Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine;
Venue
Cancer Research
Published
2009-08-31
Volume
69
Issue
17
Pages
7022-7029
ISSN
  • 0008-5472
  • 1538-7445
Cited by
91
References
4
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review